Application of a compound probiotic agent for preparing products for treating ulcerative colitis

Abstract

The application provides the application of a composite probiotic agent for preparing products for treating ulcerative colitis. The compound probiotic bacterial agent contains 4 strains of probiotic lactic acid bacteria, namely Lactobacillus casei Zhang, Bifidobacterium animalis V9, Lactobacillus plantarum P-8 and Lactobacillus plantarum C2, these probiotics all have good acid resistance, artificial Gastrointestinal fluid tolerance and bile salt tolerance, and no drug-resistant plasmids, the 4 probiotic strains contained in it all have high safety. The compound probiotic bacterial agent also includes prebiotics, which can synergize with probiotics to ensure the beneficial function of probiotics. The compound probiotic agent provided by this application has a significant curative effect on ulcerative colitis, and can regulate the probiotic function of intestinal flora so as to make the intestinal flora healthy. The compound probiotic agent provided by this application is used as a treatment for ulcerative colitis Auxiliary drugs for colitis have the characteristics of simple treatment, high remission rate, and no side effects.

Description

technical field [0001] The application belongs to the field of biological preparations, and in particular relates to the use of a compound probiotic agent for preparing products for treating ulcerative colitis. Background technique [0002] Ulcerative colitis (Ulcerative colitis, UC) is a chronic non-specific intestinal inflammatory disease with unknown etiology and pathogenesis, and is a subtype of inflammatory bowel disease (Inflammatory bowel disease, IBD). The rate is increasing year by year globally. Ulcerative colitis mainly manifests as colonic mucosal lesions, mostly ulcers, and the lesions mostly occur in the rectum and sigmoid colon, and even involve the entire colon. Currently, UC is believed to be caused by multiple factors such as genetic factors, immune dysfunction, intestinal barrier dysfunction, and changes in intestinal microecology. [0003] The traditional method of treating ulcerative colitis is to take antibiotics orally, and antibiotics have low selec...

AI Technical Summary

Problems solved by technology

[0003] The traditional method of treating ulcerative colitis is to take antibiotics orally, and antibiotics have low selectivity to the intestinal flora. When the pathogenic bacteria in the intestinal tract are killed, the probiotics in the intestinal tract will also be destroyed in large quantities. Kill, and then disrupt the balance of the intestinal flora of patients, resulting in a lower rate of remission of ulcerative colitis

Images